FDA OK's Regeneron's Eylea in diabetic retinopathy
This article was originally published in Scrip
Regeneron Pharmaceuticals' Eylea (aflibercept) won the FDA's approval on 25 March as a treatment for diabetic retinopathy in patients with diabetic macular edema (DME).
You may also be interested in...
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.